CB2 Insights Inc.

CNSX: CBII


Canadian symbol: CBII.CN
US symbol: CBIIF

Currency in CAD

Valuation Measures

Market Cap (intraday) 57.46M
Enterprise Value 313.01M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)0.56
Price/Book (mrq)5.29
Enterprise Value/Revenue 30.97
Enterprise Value/EBITDA 6-2.64

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-50.00%
S&P500 52-Week Change 36.72%
52 Week High 30.2100
52 Week Low 30.0550
50-Day Moving Average 30.1185
200-Day Moving Average 30.1083

Share Statistics

Avg Vol (3 month) 384.54k
Avg Vol (10 day) 353.59k
Shares Outstanding 582.84M
Float 54.56M
% Held by Insiders 120.81%
% Held by Institutions 10.00%
Shares Short (Jun. 14, 2020) 462.86k
Short Ratio (Jun. 14, 2020) 41.2
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 40.08%
Shares Short (prior month May 14, 2020) 410.47k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Dec. 30, 2019

Profitability

Profit Margin -81.75%
Operating Margin (ttm)-40.92%

Management Effectiveness

Return on Assets (ttm)-33.69%
Return on Equity (ttm)-303.30%

Income Statement

Revenue (ttm)13.42M
Revenue Per Share (ttm)0.17
Quarterly Revenue Growth (yoy)27.60%
Gross Profit (ttm)9.32M
EBITDA -4.93M
Net Income Avi to Common (ttm)-10.97M
Diluted EPS (ttm)-0.1420
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)130.27k
Total Cash Per Share (mrq)0
Total Debt (mrq)5.68M
Total Debt/Equity (mrq)409.51
Current Ratio (mrq)0.07
Book Value Per Share (mrq)0.02

Cash Flow Statement

Operating Cash Flow (ttm)-1.15M
Levered Free Cash Flow (ttm)404.56k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CBII.CN
CB2 Insights
2 weeks ago
CBII.CN
CB2 Insights
2 months ago
CBII.CN
CB2 Insights
2 months ago
CBII.CN
CB2 Insights
2 months ago
CBII.CN
CB2 Insights
2 months ago
CBII.CN
CB2 Insights
6 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
8 months ago
CBII.CN
CB2 Insights
8 months ago
CBII.CN
CB2 Insights
8 months ago
CBII.CN
CB2 Insights
10 months ago
CBII.CN
CB2 Insights
11 months ago
CBII.CN
CB2 Insights
12 months ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
20.81%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by CB2 Insights Inc.


CB2 Insights Announces Q1 Financial Statements to be filed on or before July 14, 2020

CB2 Insights Announces Q1 Financial Statements to be filed on or before July 14, 2020

TORONTO, June 29, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), announces that it intends to rely on the temporary blanket relief for market participants published on March 23, 2020 (the “Blanket Order”) by the Canadian Securities Administrators (the “CSA”) which provides for a 45-day extension to file its ... Read More...
CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%

CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%

TORONTO, June 18, 2020 -- CB2 Insights (CSE: CBII; OTCQB: CBIIF) (“CB2” or the “Company”), one of the largest integrative healthcare system in the United States, today reported its audited consolidated financial results for the year ended December 31, 2019. Additional information concerning the Company, including its unaudited condensed c... Read More...
CB2 Insights Announces Amendments to Promissory Note held by Merida Capital Partners

CB2 Insights Announces Amendments to Promissory Note held by Merida Capital Partners

TORONTO, June 18, 2020 -- CB2 Insights (CSE: CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces that it has amended the terms of its issued and outstanding promissory note held by Merida Capital Partners (“Merida”), which is designed to help the Company achieve its long term growth plans and drive continued profitability.Amendment to... Read More...
CB2 Insights Announces Delay in Filing Annual Financial Statements

CB2 Insights Announces Delay in Filing Annual Financial Statements

TORONTO, June 15, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF) announces that it has been delayed in filing its annual financial statements (the “Annual Financial Statements”) and associated management discussion and analysis (“MD&A”) for the year-ended December 31, 2019, which were required to be filed... Read More...
CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call

CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call

TORONTO, June 10, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces an update further to its news release of April 20, 2020, with respect to: (i) the filing its audited annual financial statements for the year ended December 31, 2019 and the related management discussion and analysis (“MD&A”); and (ii) ... Read More...
CB2 Insights Announces Unaudited Profitability in April and Continued Execution of its Business Plan

CB2 Insights Announces Unaudited Profitability in April and Continued Execution of its Business Plan

TORONTO, May 07, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has achieved its target of reaching profitability. On an unaudited basis, the Company has seen positive EBITDA for April 2020. Amidst the ever-evolving COVID-19 pandemic, the Company continues to work hard to prioritize achieving... Read More...
CB2 Insights Introduces Insurable Medical Services to Patients in the United States with Launch of Skylight Health Group

CB2 Insights Introduces Insurable Medical Services to Patients in the United States with Launch of Skylight Health Group

TORONTO, April 29, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has officially launched its newest division Skylight Health Group (“SHG”) as part of its clinical operations in the United States. SHG will immediately provide a range of integrated health services from primary medical care, to... Read More...
CB2 Insights Completes Purchase of Colorado-based Relaxed Clarity with Surpassed Initial Targets and Provides Additional Corporate Updates

CB2 Insights Completes Purchase of Colorado-based Relaxed Clarity with Surpassed Initial Targets and Provides Additional Corporate Updates

TORONTO, April 20, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has completed the terms of the purchase agreement of Colorado-based Rae of Sunshine Health Services (“ROSH”; “Relaxed Clarity”).  CB2 announced the purchase and took over operations for the multi-location clinic group in April ... Read More...
CB2 Insights Announces Delay in Filing Under CSA Instrument Governing Relief under COVID-19 Duress

CB2 Insights Announces Delay in Filing Under CSA Instrument Governing Relief under COVID-19 Duress

TORONTO, April 15, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that due to circumstances created by the COVID – 19 pandemic it will not be filing its Financial Statements for the Fiscal Year ended December 31, 2020 by the scheduled due date of April 30, 2020 (as required by section 4.4(b) of Natio... Read More...
CB2 Insights Launches Industry's First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

TORONTO, March 30, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has launched the medical cannabis industry’s first interactive dashboard which gives any industry stakeholders acc... Read More...
CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

TORONTO, Jan. 29, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors. Effec... Read More...
CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

TORONTO, Jan. 27, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announces it has completed all payment obligations for the June 2019 acquisition of New Jersey Alternative Medicine... Read More...
CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

TORONTO, Jan. 08, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today released its CEO’s 2019 Year In Review.  The letter, which has also been sent to Investors, provides an updat... Read More...
CB2 Insights Announces Industry's First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused on patients with anxietyAnnouncement follows the passage of the 2018 US Farm Bill which legalized the mass production of hemp, a form of cannabis with lower THC levels than marijuana, across the United StatesPartnership follows t... Read More...
CB2 Insights Launches Warrant Incentive Program

CB2 Insights Launches Warrant Incentive Program

TORONTO, Dec. 11, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-26of-care to the medical cannabis community, announces a warrant exercise incentive program (the “Program”) which has been implemented to encourage the exerci... Read More...
CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

TORONTO, Dec. 03, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced that it is partnering with Licensed Producer FCM Global (“FCM”), the first Colombian cannabis compa... Read More...
CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

TORONTO, Nov. 14, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting with invest... Read More...
CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

TORONTO, Nov. 08, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced its results for the three and nine months ended September 30, 2019. All figures are reported in Canadian ... Read More...
CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights’ Q3 2019 preliminary unaudited revenue saw a sequential growth of approximately 29% compared to the previous quarterCompany’s Q3 preliminary Adjusted-EBITDA loss was significantly reduced by 64% compared to the previous quarterAfter three acquisitions in the year, CB2 Insights now owns and operates one of the the largest netw... Read More...
CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK

CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK

Company strengthens market presence in United Kingdom with licensing of Electronic Data Capture Technology in partnership with UK-based MyAccess ClinicsMyAccess Clinics to use CB2’s software within multi-clinic operation in the UK for data input and managementSoftware will allow MyAccess Clinics to capture comprehensive data sets related ... Read More...
CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus

CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus

Company recruits prominent Colombian naturopathic and integrative medicine physician Dr. Paola Cubillos, MD, ND to lead medical cannabis research programs to advance emerging marketRapid growth in market presence from Licensed Producers and cannabis-focused product manufacturers create prime conditions to immediately leverage Company’s te... Read More...
CB2 Insights Reports Second Quarter Fiscal 2019 Financial Results, Sees Positive Impact from New Acquisitions

CB2 Insights Reports Second Quarter Fiscal 2019 Financial Results, Sees Positive Impact from New Acquisitions

TORONTO, Aug. 28, 2019 -- CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the second quarter of 2019.  Additional information concerning the Company, incl... Read More...
CB2 Insights Announces New Appointment to Board of Directors with Medical Cannabis and Capital Markets Executive

CB2 Insights Announces New Appointment to Board of Directors with Medical Cannabis and Capital Markets Executive

TORONTO, Aug. 01, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed corporate finance executive and cannabis industry expert, Gerry Goldberg as Director on its Board.&nb... Read More...
CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

NEWS HIGHLIGHTSCB2 Insights has been selected as exclusive research technology platform for the UK’s largest medical cannabis Pilot - Project TWENTY21Project TWENTY21 aims to enroll 20,000 patients into the Pilot and CB2 Insights was selected as the platform on which to build the patient registry and generate Real-World Evidence throughou... Read More...
CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations

CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations

TORONTO, July 09, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has successfully completed Phase One of its Clinical Decision Support (CDS) tool integration including targeted use... Read More...
Premier Health and CB2 Insights Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluation

Premier Health and CB2 Insights Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluation

VANCOUVER, British Columbia, July 09, 2019 -- Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, has successfully completed Phase One of CB2... Read More...
CB2 Insights Expands Clinical Division into New Jersey with the Asset Acquisition of New Jersey Alternative Medicine Clinics

CB2 Insights Expands Clinical Division into New Jersey with the Asset Acquisition of New Jersey Alternative Medicine Clinics

TORONTO, June 25, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it will take over patient care for one of New Jersey’s largest medical cannabis evaluation and educ... Read More...
CB2 Insights Announces Annual General & Special Meeting of Shareholders and Corporate Update

CB2 Insights Announces Annual General & Special Meeting of Shareholders and Corporate Update

TORONTO, June 24, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has announced the date of its first Annual General Meeting (AGM) and Special Meeting of Shareholders on June 27, 20... Read More...
CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

TORONTO, May 30, 2019 -- CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including it... Read More...
CB2 Insights Inc., Tools to Help Physicians Prescribe Medical Cannabis, CEO Clip Video

CB2 Insights Inc., Tools to Help Physicians Prescribe Medical Cannabis, CEO Clip Video

Vancouver, British Columbia--(Newsfile Corp. - May 3, 2019) - Prad Sekar, CEO of CB2 Insights, explains how the company uses data tools to help practitioners integrate medical cannabis.If you cannot view the video above, please visit:https://www.b-tv.com/cb2-insights-ceo-clip-90sec/CB2 Insights Inc. is being featured on BNN Bloomberg on M... Read More...
CB2 Insights Expands Board with Teladoc Executive Marc Adelson,  Appoints David Danziger as Chairman and Adopts Advance Notice Bylaw

CB2 Insights Expands Board with Teladoc Executive Marc Adelson,  Appoints David Danziger as Chairman and Adopts Advance Notice Bylaw

TORONTO, May 02, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII) (OTCQB:CBTOF) a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real-World Evidence, today announced the addition of a new Director to its Board as well as the appointment of its new Chairman.Joining the Board ... Read More...
CB2 Insights Announces FY2018 Financial Results After Transformative Year

CB2 Insights Announces FY2018 Financial Results After Transformative Year

TORONTO, April 30, 2019 -- CB2 Insights (CSE:CBII; OTCQB:CBTOF) (“CB2” or the “Company”), a leading data-analytics company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today reported its results for the fiscal year ending December 31, 2018.  Additional information concerning... Read More...
CB2 Insights Completes Acquisition of Cannabis Evaluation Clinics in Arizona and Colorado

CB2 Insights Completes Acquisition of Cannabis Evaluation Clinics in Arizona and Colorado

Acquisition further strengthens medical cannabis data company’s financial metrics and data asset; reaching more than 85,000 patient evaluations per yearTORONTO, April 10, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII), a leading provider of predictive analytics tools, data-driven software and comprehensive services across the ca... Read More...
CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity

CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity

Accretive acquisition of Colorado-based clinic group bolsters Company’s US medical cannabis clinical roll-up strategy; adds 15,000 new patientsTORONTO, April 04, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII), a leading provider of predictive analytics tools, data-driven software and comprehensive services across the cannabis va... Read More...
CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool

CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool

First-of-its-Kind EMR Platform Integration to Provide Tool for Nearly 5,000 Physicians and Healthcare Practitioners to Qualify and Prescribe Medical CannabisTORONTO, March 27, 2019 -- CB2 Insights (CSE:CBII) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the... Read More...
Premier Health Signs Agreement with CB2 Insights to Integrate Medical Cannabis Clinical Decision Support Tool

Premier Health Signs Agreement with CB2 Insights to Integrate Medical Cannabis Clinical Decision Support Tool

Data-Driven Technology Firm Begins a First-of-its-Kind Integration with EMR Platform to Provide Nearly 5,000 Physicians and Healthcare Practitioners a Tool to Qualify and Prescribe Medical CannabisVANCOUVER, British Columbia, March 27, 2019 -- Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health... Read More...
CB2 Insights Signs Agreement to Acquire Medical Cannabis Clinic Group in Colorado and Arizona

CB2 Insights Signs Agreement to Acquire Medical Cannabis Clinic Group in Colorado and Arizona

First acquisition post-RTO to consolidate the US medical cannabis clinical market; increases revenues, patient count and jurisdictions servedTORONTO, March 20, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII), a leading provider of predictive analytics tools, data-driven software and comprehensive services across the cannabis valu... Read More...
Artificial Intelligence Pioneer Dr. Randy Goebel Joins CB2 Insights to Advance its Predictive Insights Platform

Artificial Intelligence Pioneer Dr. Randy Goebel Joins CB2 Insights to Advance its Predictive Insights Platform

Globally-Recognized Machine Learning Expert Joins as Senior Advisor to Data Insights DivisionTORONTO, March 14, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII) a leading global provider of predictive analytics tools, data-driven software and comprehensive services across the medical cannabis value chain, today announced that Dr. ... Read More...
CB2 Insights Retires Convertible Debentures

CB2 Insights Retires Convertible Debentures

TORONTO, March 13, 2019 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE:CBII), has completed the conversion of 100% of its outstanding Convertible Senior Secured Debentures entered into between May and September of 2017, retiring C$959,000 of principal, accrued interest and any outstanding fees through the issuance of 7,524,207 common ... Read More...
Coming Soon.

Delayed data (1h)


Share this page